Drugs / Teicoplanin
Teicoplanin
also known as
MDL 507 · NSC-759183 · Tagocid · Targocid · Targosid · Teichomycin a2 · Teicoplanin a2 · teicoplanin: targocid 200 mg vial. · +4 more
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04176328 | Oct 2019 → Sep 2020 | cystic fibrosis | Neupharma Srl | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01815541 | Mar 2013 → Jun 2015 | infective arthritis | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04341831 | Apr 2020 → Jan 2021 | lumbar disk disease, lumbar spinal stenosis, scoliosis, spondylolisthesis | Bezmialem Vakif University | Unknown | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT05914467 | Aug 2023 → Apr 2026 overdue | gram-positive bacterial infections | Radboud University Medical Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04370145 | May → Oct 2021 | cholangitis | Tongji Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04003818 | May 2020 → Jan 2021 | Clostridium difficile colitis | Sanofi | Terminated | No outcome recorded |
| Phase 4 | NCT01592032 | May 2012 → Jan 2015 | bacterial infectious disease, prosthesis-related infectious disease | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
| Phase 4 | NCT00368498 | Jun 2006 → Dec 2007 | staphylococcal infection | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00719056 | Aug 2004 → Dec 2005 | — | University of Athens | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02652169 | Jun 2014 → Dec 2025 overdue | chronic ulcer of skin | Medical University of Vienna | Recruiting | No outcome recorded |
| — | NCT00024453 | Feb 1999 → Dec 2009 | infectious disease | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00925093 Comparator | Sep 2011 → Dec 2012 | — | Aarhus University Hospital | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00428844 Comparator | Jun 2007 → Mar 2010 | osteomyelitis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT00430937 Comparator | Apr 2006 → Mar 2008 | skin infection | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07590648 Background | Jun 2026 → Jul 2028 expected | bacterial infectious disease, childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm, neutropenia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02018094 Comparator | Oct 2013 → Mar 2014 | skin infection | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT00454272 Comparator | Jan 2005 → Aug 2007 | infectious disease, neutropenia | Sanofi | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06818565 Background | Feb 2025 → Dec 2026 expected | liver disorder | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT02288923 Comparator | Mar 2015 → Jul 2018 | osteoarthritis, knee | Royal Devon and Exeter NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | teicoplanin | “Drug stop within 24 hours after randomization:Piperacillin-tazobactam, amikacin, meropenem, cefepime, ceftazidime, vancomycin, teicoplanin, ciprofloxacin, levofloxacine and...” NCT07590648 ↗20“Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction).” NCT02288923 ↗ “* Teicoplanin : 10mg/kg/12h for 5 dosis in combination, then in monotherapy.” NCT05074147 ↗ “T eicoplanin” NCT02099240 ↗ |
| Known as | MDL 507 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | NSC-759183 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | Tagocid | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | Targocid | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | Targosid | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | Teichomycin a2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | Teicoplanin a2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | teicoplanin: targocid 200 mg vial. | “teicoplanin: targocid 200 mg vial.” NCT01592032 ↗ |
| Known as | Teicoplanina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | Teicoplanine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | Teikoplanin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Known as | Ticocin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297166 ↗ |
| Action | Inhibit | “acts by inhibition of cell wall synthesis” NCT04176328 ↗ |
| Modality | Other / unclassified | “Teicoplanin and vancomycin, are two glycopeptide antibiotics currently in widespread use and are active against MRSA.” NCT04176328 ↗ |
| Route | Intravenous | “teicoplanin IV bolus every 12 hours for 3 doses” NCT00024453 ↗ |